GoHealth Inc. Faces Revenue Challenges in 2025 Q2 Amid Strategic Adjustments

GoHealth Inc. (NASDAQ: GOCO) experienced a challenging second quarter in 2025, marked by an 11.2% year-over-year decrease in net revenues to $94.0M. This decline was primarily due to reductions in partner and non-agency revenues by 44.4% and 79.4%, respectively, though partially offset by a notable increase in other revenues, particularly from the GoHealth Protect initiative. The company attributes this downturn to broader market softness, a factor management is actively addressing through strategic adjustments and market responsiveness.

In a move to strengthen its financial position, GoHealth secured a new senior secured super priority term loan facility, introducing $80.0M in new capital. This development not only ensures compliance with current debt covenants but also opens the door for potential acquisitions, supported by a $250.0M debt basket. The lenders' confidence in GoHealth's growth potential is further underscored by the equity stake included in this transaction. Additionally, amendments to the existing debt facility provide a reset of financial covenants and a temporary halt in interest rate payments until 2026, offering the company much-needed breathing room to focus on the upcoming Annual Enrollment Period (AEP).

Sales performance in the second quarter reflected the industry-wide macroeconomic challenges, with sales per submission dropping by 4.8% year-over-year to $657. Despite this, the GoHealth Protect initiative emerged as a bright spot, generating $8.7M in other revenues. The company is optimistic that further integration of this initiative will help stabilize revenue streams. On the cost front, GoHealth demonstrated effective management, reducing the average cost of customer acquisition (CAC) by 4.8% to $613, despite slight margin contractions. Efforts to enhance call center productivity, agent training, and marketing strategies are expected to further improve cost efficiency.

Valuation analyses, based on EV/EBITDA comparisons, suggest a potential range for GoHealth's stock price between $11.45 and $15.40, with a midpoint of $13.43. This assessment considers the company's projected FY26 EBITDA and aligns its valuation more closely with industry peers. As GoHealth navigates through these challenges, its strategic initiatives and focus on the upcoming AEP are critical to its recovery and long-term growth trajectory.